Sangamo Therapeutics Inc Stock Price, News & Analysis

Sangamo Therapeutics (NASDAQ: SGMO) has made significant strides in its clinical pipeline, including advancements in its Phase 1/2 STAAR study for Fabry disease, where 20 patients have been dosed. The company has also initiated the dosing of a third patient in the TX200 CAR-Treg study for kidney transplantation, with regulatory feedback supporting dose escalation. Additionally, Sangamo has prioritized its neurology pipeline by introducing the Nav1.7 target for chronic neuropathic pain, expecting IND submission in 2024. However, a corporate restructuring will reduce the workforce by 27%, aiming for annual cost savings of approximately $31 million. Preliminary Q1 2023 revenue is projected at $158 million, a sharp rise from $28.2 million in Q1 2022, mainly due to collaboration agreements with Biogen. Total operating expenses are anticipated to range from $120 million to $140 million, reflecting impairment charges related to recent collaborations.

Sangamo Therapeutics, a genomic medicine company, is set to release its first quarter 2023 financial results after market close on April 26, 2023. A conference call will follow on April 27, 2023 at 8:30 a.m. ET, open to the public for financial and business updates.

Participants can register for the call via a provided link, with options to dial in or use a direct phone connect. A replay will be accessible post-call under the company's 'Events and Presentations' section.

Sangamo is focused on innovative genomic medicines, leveraging proprietary technologies to address unmet medical needs. For more information, visit their website.

Sangamo Therapeutics (SGMO) recently announced its fourth quarter and full year 2022 financial results, reporting a consolidated net loss of $52.0 million for Q4 and $192.3 million for the year. Revenues for Q4 were $27.2 million, a slight decrease from $28.0 million in 2021, while total revenues for 2022 increased to $111.3 million from $110.7 million. Key updates include promising data from the Fabry disease study, with 78% Gb3 substrate clearance at 6 months, and plans for a Phase 3 trial expected by late 2023. The company aims to optimize resources toward Fabry, CAR-Treg, and CNS programs in 2023.

Sangamo Therapeutics (Nasdaq: SGMO) released new preliminary data from its Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. As of October 20, 2022, 13 patients have shown sustained, elevated levels of alpha-galactosidase A activity for over two years. Key findings include a 78% reduction in Gb3 substrate and a significant decrease in urine podocyte loss. The study is progressing towards a potential Phase 3 trial by the end of 2023. Furthermore, patients have demonstrated improved general health scores. This study may provide a transformative treatment option, reducing reliance on enzyme replacement therapy.

Sangamo Therapeutics (Nasdaq: SGMO) is set to host a conference call on February 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter and full year 2022 financial results and business updates. Prior to this call, the company will release its financial results. Participants can register for the call using this link. An updated corporate presentation will also be available for review.

Sangamo Therapeutics (SGMO) reported its third quarter 2022 results, highlighting significant advancements in its clinical pipeline. The company announced promising preliminary data from the Phase 1/2 STAAR study for Fabry disease, resumed recruitment for the Phase 3 AFFINE trial for Hemophilia A, and continues dosing in various studies, including sickle cell and renal transplant rejection. Financially, SGMO posted a net loss of $53.2 million, with revenues of $26.5 million. Despite a decrease in revenues, the company narrowed its expense guidance for 2022, projecting total operating expenses between $315 million and $325 million.

Sangamo Therapeutics (NASDAQ: SGMO) announced it will release its third quarter 2022 financial results on November 3, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide business updates. Participants can register for the call through a provided link and are encouraged to join 10 minutes early. A replay will be available post-call.

Sangamo focuses on developing genomic medicines through gene therapy, cell therapy, and genome engineering.

Sangamo Therapeutics has provided updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. As of July 21, 2022, nine patients exhibited elevated α-Gal A activity, showing up to a 30-fold increase for up to 23 months post-dosing. The therapy was well tolerated with no serious adverse events reported. The study has transitioned to an expansion phase, and the company is planning a Phase 3 trial. These results were presented at the ESGCT 2022 congress and suggest ST-920 could serve as an alternative to enzyme replacement therapy.